Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study for the Transdermal Application of Teriparatide

This study has been completed.
Sponsor:
Collaborator:
TransPharma Medical
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01011556
First received: November 9, 2009
Last updated: September 21, 2012
Last verified: September 2012

November 9, 2009
September 21, 2012
November 2009
September 2011   (final data collection date for primary outcome measure)
Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 12 Months [ Time Frame: Baseline, 12 Months ] [ Designated as safety issue: No ]
Bone mineral density (BMD) of the lumbar spine was assessed by dual energy X-ray absorptiometry (DXA). BMD values are corrected data and have been standardized across the machine types (Hologic and Lunar). Analyses were performed using ANCOVA model and least square (LS) means were adjusted for baseline BMD values as a covariate and pooled site and treatment as fixed effects.
Percent Change from Baseline in Lumbar Spine Bone Mineral Density (BMD) at 12 months [ Time Frame: Baseline, 12 Months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01011556 on ClinicalTrials.gov Archive Site
  • Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 6 Months [ Time Frame: Baseline, 6 Months ] [ Designated as safety issue: No ]
    Bone mineral density (BMD) of the lumbar spine was assessed by dual energy X-ray absorptiometry (DXA). BMD values are corrected data and have been standardized across the machine types (Hologic and Lunar). Analyses were performed using ANCOVA model with the baseline value as a covariate and pooled site and treatment as fixed effects.
  • Time Course Change of BMD Response at the Lumbar Spine [ Time Frame: Baseline to 6 Months and 12 Months ] [ Designated as safety issue: No ]
    To assess the time course of the treatment, the BMD data of the lumbar spine was assessed by dual energy X-ray absorptiometry (DXA) and analyzed using a mixed model repeated measures (MMRM) method, with the repeated measure occurring at each visit (for example, 6 and 12 month). BMD values are corrected data and have been standardized across the machine types (Hologic and Lunar).
  • Percent Change From Baseline in Procollagen Type 1 N-Terminal Propeptide (P1NP) [ Time Frame: Baseline, 1 Month, 3 Months, 6 Months, 12 Months ] [ Designated as safety issue: No ]
    Procollagen Type 1 N-Terminal Propeptide (P1NP) is a marker of bone formation.
  • Percent Change From Baseline of C-Terminal Telopeptide (CTX) [ Time Frame: Baseline, 1 Month, 3 Months, 6 Months, 12 Months ] [ Designated as safety issue: No ]
    C-terminal telopeptide is a marker of bone resorption.
  • Percent Change From Baseline in Serum Procollagen Type 1 C-Propeptide (P1CP) at 1 Month [ Time Frame: Baseline, 1 Month ] [ Designated as safety issue: No ]
    Procollagen Type 1 N-Terminal Propeptide (P1NP) is a marker of bone formation.
  • Convenience/Ease of Use Questionnaire (CEUQ) [ Time Frame: baseline up to 12 months ] [ Designated as safety issue: No ]
    CEUQ consists of 5 sections and 16 questions using a 5-point Likert scale designed to collect measures for ease of use (S1), convenience of use (S2), confidence of use (S3), fear of use (S4), and overall satisfaction with therapy (S5). CEUQ is not a validated instrument.
  • Change in Serum Calcium With and Without Adjustments for Serum Albumin From Predose to After 4 and 6 Hours [ Time Frame: Baseline, 12 Months ] [ Designated as safety issue: Yes ]
    Serum calcium adjusted for serum albumin levels is calculated using the following formula: Total Calcium + [(40 - albumin) x 0.02]. Analysis for serum calcium and albumin adjusted serum calcium were collected at predose, 4 hours (h) post-dose (PD) and 6 h PD at baseline and 12 months (mon).
  • Change From Baseline in Urine Calcium Excretion at 6 and 12 Months [ Time Frame: Baseline, 6 Months, 12 Months ] [ Designated as safety issue: Yes ]
  • Change From Pre-dose and Postdose Supine and Standing SBP and DBP at Baseline (BL) and 12 Months (Mon) [ Time Frame: Pre-Dose, 30 minutes, 2 hours Post-Dose at Baseline and 12 Months ] [ Designated as safety issue: Yes ]
    Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) measured at pre-dose and 30 minutes (min) and 2 hours (hr) post-dose in both the supine and standing position.
  • Change From Pre-dose to Postdose in Supine and Standing Heart Rate at Baseline (BL) and 12 Months (Mon). [ Time Frame: Pre-dose, 30 minutes, 2 hours at Baseline and 12 Months ] [ Designated as safety issue: Yes ]
  • Number of Participants With Parathyroid Hormone (PTH) Specific Antibody Levels [ Time Frame: Baseline and 1, 3, 12, and 13 Months (mon) ] [ Designated as safety issue: No ]
    Participants were tested for anti-recombinant teriparatide and anti-synthetic teriparatide titers. Either none were detected (ND) or antibodies were determined to be present if the teriparatide specific antibody titers were at least 1:8 (titer 1:8).
  • Pharmacokinetics Parameters: Area Under the Curve (AUC) [ Time Frame: Baseline, 1 Month, 3 Months, and 12 Months ] [ Designated as safety issue: No ]
    Due to high intra-subject variability, data was not analyzed for this outcome measure.
  • Pharmacokinetics Parameters: Maximal Concentration (Cmax) [ Time Frame: Baseline, 1 Month, 3 Months, 12 Months ] [ Designated as safety issue: No ]
    Due to high intra-subject variability, data was not analyzed for this outcome measure.
  • DRAIZE Edema Assessment at Baseline Through 13 Month Follow-up [ Time Frame: 13 Month follow-up ] [ Designated as safety issue: Yes ]
    Severity of edema was categorized based on a 5 point scale: 0=no edema, 4=severe edema (defined as an area raised more than 1 millimeter and extending beyond area of exposure)
  • DRAIZE Erythema Assessment at Baseline Through 13 Month Follow-up [ Time Frame: 13 Month follow-up ] [ Designated as safety issue: Yes ]
    Severity of erythema was categorized based on a 5 point scale: 0=no erythema, 4=severe erythema (defined as beet red to eschar)
  • Percent Change from Baseline in Lumbar Spine BMD at 6 months [ Time Frame: Baseline, 6 Months ] [ Designated as safety issue: No ]
  • Percent Change from Baseline in Procollagen Type 1 N-Terminal Propeptide (P1NP) at 1 and 3 months [ Time Frame: Baseline, 1 Month, 3 Months ] [ Designated as safety issue: No ]
  • Percent Change from Baseline of C-Terminal Telopeptide (CTX) at 1 and 3 months [ Time Frame: Baseline, 1 Month, 3 Months ] [ Designated as safety issue: No ]
  • Change from Baseline in Serum Procollagen Type 1 C-Propeptide (P1CP) at 1 month [ Time Frame: Baseline, 1 Month ] [ Designated as safety issue: No ]
  • Convenience/Ease of Use Questionnaire (CEUQ) at 12 months [ Time Frame: 12 Months ] [ Designated as safety issue: No ]
  • Change in Serum Calcium with and without Adjustments for Serum Albumin from Predose to after 4 and 6 hours [ Time Frame: Baseline, 3 Months, 6 Months, 12 Months ] [ Designated as safety issue: Yes ]
  • Change from Baseline in Urine Calcium Excretion at 6 and 12 months [ Time Frame: Baseline, 6 Months, 12 Months ] [ Designated as safety issue: Yes ]
  • Difference in Supine to Standing Systolic and Diastolic Blood Pressure at Predose, 30 minutes prior, 30 minutes, and 2 hour Postdose [ Time Frame: Baseline, 1 Month, 3 Months, 6 Months, 8 Months, 12 Months ] [ Designated as safety issue: Yes ]
  • Difference in Supine to Standing Pulse Rate Measured at Predose, 30 minutes prior, 30 minutes, and 2 hour Postdose [ Time Frame: Baseline, 1 Month, 3 Months, 6 Months, 8 Months, 12 Months ] [ Designated as safety issue: Yes ]
  • PTH Antibody levels at 12 Months [ Time Frame: 12 Months ] [ Designated as safety issue: No ]
  • Pharmacokinetics Parameters: Area Under the Curve (AUC) from Post dose 30 minutes to 4 hours [ Time Frame: Baseline, 1 Month, 3 Months, and 12 Months ] [ Designated as safety issue: No ]
  • Pharmacokinetics Parameters: Maximal Concentration (Cmax) from Post Dose 30 minutes to 4 hours [ Time Frame: Baseline, 1 Month, 3 Months, 12 Months ] [ Designated as safety issue: No ]
  • DRAIZE Edema Assessment at Baseline through 13 Months followup [ Time Frame: Baseline through 13 month follow up ] [ Designated as safety issue: Yes ]
  • DRAIZE Erythema Assessment at Baseline through 13 Months followup [ Time Frame: Baseline through 13 month follow up ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
A Study for the Transdermal Application of Teriparatide
A Phase 2 Study for Transdermal Application of Teriparatide

The primary purpose of this study is to help answer the following research questions:

  1. How teriparatide given using a skin patch (transferred through the skin using the ViaDerm Teriparatide System) compares to teriparatide injected under the skin with a needle (pen injector) affects your bone density (how solid or porous your bones are).
  2. The safety of the teriparatide skin patch and any side effects that might be associated with it.

Teriparatide 20 micrograms (mcg) per day is currently only available as a subcutaneous (SQ) injection and many patients with severe osteoporosis for whom anabolic therapy with teriparatide is appropriate are either unwilling or physically unable to self-inject. The purpose of this Phase 2 study is to identify a transdermal dose or doses that will be comparable to the teriparatide 20 mcg SQ dose from a pharmacodynamic (PD) and safety standpoint for use in future Phase 3 studies.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Osteoporosis
  • Drug: Subcutaneous Teriparatide
    Administered subcutaneously once daily for 12 months
    Other Names:
    • recombinant human parathyroid hormone (rhPTH) (1-34)
    • recombinant human teriparatide
    • Forteo
    • Forsteo
    • LY333334
  • Drug: Transdermal Teriparatide
    Administered transdermally, applied once daily for 6 hours over 12 months
    Other Names:
    • synthetic human parathyroid hormone (shPTH) (1-34)
    • synthetic human teriparatide
  • Active Comparator: 20 mcg Subcutaneous Teriparatide
    Received 20 micrograms (mcg) subcutaneously once daily in an unblinded manner.
    Intervention: Drug: Subcutaneous Teriparatide
  • Experimental: 30 mcg Transdermal Teriparatide
    Received 30 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.
    Intervention: Drug: Transdermal Teriparatide
  • Experimental: 50 mcg Transdermal Teriparatide
    Received 50 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.
    Intervention: Drug: Transdermal Teriparatide
  • Experimental: 80 mcg Transdermal Teriparatide
    Received 80 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.
    Intervention: Drug: Transdermal Teriparatide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
233
September 2011
September 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Ambulatory, postmenopausal women.
  • Centrally confirmed lumbar spine or femoral neck bone mineral density (BMD) T-score of less than or equal to -2.5.
  • Without language barrier, cooperative, expected to return for all follow-up procedures, and have given informed consent after being informed of the risks, medications, and procedures to be used in the study.
  • Able to use the pen-type injection delivery system and the ViaDerm Teriparatide System satisfactorily in the opinion of the investigator, or with the help of a family member or caregiver.
  • Able to be reached by telephone for follow-up contact between visits

Exclusion Criteria:

  • Abnormal laboratory values for albumin and alkaline phosphatase.
  • Laboratory values outside the ranges defined in the protocol for the following: Serum calcium, intact parathyroid hormone (iPTH), 25 hydroxyvitamin D, and 24-hour urine calcium
  • History of diseases other than postmenopausal osteoporosis that affect bone metabolism, such as Paget's disease, renal osteodystrophy, osteomalacia, any secondary causes of osteoporosis, hypoparathyroidism, hyperparathyroidism, and intestinal malabsorption.
  • History of malignant neoplasms in the 5 years prior to randomization, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated. Patients with carcinoma in situ of the uterine cervix treated definitively more than 1 year prior to entry into the study may be randomized.
  • Use of a pacemaker.
  • Known chronic dermatological disorder, such as contact dermatitis
  • History of allergy or sensitivity to tapes or adhesives
  • Patients prone to bleeding with coagulopathies, such as hemophilia or thrombocytopenia.
  • Patients who have an increased baseline risk of osteosarcoma, Paget's disease of the bone, or unexplained elevations of alkaline phosphatase; or prior external beam, implant radiation therapy involving the skeleton, or previous primary skeletal malignancy.
  • Major fracture within the past year in the femur, tibia, humerus, or radius (with or without ulna).

Treatment with:

  • calcitonins in the 2 months prior to randomization.
  • oral, transdermal/patch, or injectable estrogens, progestins, estrogen analogs, estrogen agonists, estrogen antagonists, selective estrogen receptor modulators, or tibolone in the 3 months prior to randomization; treatment with intravaginal estrogens in doses higher than 0.3 mg of conjugated equine estrogen, or the equivalent, for more than 3 doses per week in the 3 months prior to randomization.
  • androgens or other anabolic steroids in the 6 months prior to randomization.
  • fluorides in the 2 years prior to randomization. (Previous or current use of fluoridated water or topical dental fluoride treatments are permitted.)
  • oral bisphosphonates for more than 2 consecutive months in the 6 months prior to randomization; treatment with intravenous bisphosphonates in the 6 months prior to randomization; treatment with more than 1 cycle of intermittent oral bisphosphonates in the 6 months prior to randomization; or having received the last cycle of this intermittent oral regimen less than 4 weeks prior to screening.
  • patients receiving intravenous zoledronic acid during the 12 months prior to randomization.
  • vitamin D greater than 50,000 International Units (IU) per week or with any dose of calcitriol or vitamin D analogs or agonists in the 6 months prior to randomization.
  • systemic corticosteroids in the 1 month prior to randomization or for more than 30 days in the 1 year prior to randomization. (Ophthalmic, otic, topical, orally inhaled, nasally inhaled, or intra-articular corticosteroid therapy may be used without these restrictions.)
  • any other drug known to significantly affect bone metabolism in the 6 months prior to randomization.
  • warfarin or other coumadin anticoagulants in the 1 month prior to randomization.
  • any investigational drug in the 1 month prior to entry into the study.
Female
55 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Argentina,   Estonia,   Hungary,   Mexico,   Romania
 
NCT01011556
12641, I2Y-MC-GHFA(c)
Yes
Eli Lilly and Company
Eli Lilly and Company
TransPharma Medical
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
September 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP